IPCALAB share price target 2026

BazaarBaazi does not publish a SEBI-registered price target on IPCALAB. The desk reads structural support and resistance inside each show against the printed spot; the most recent editorial line is Systematic Read on 21 Jul 2026.

The BazaarBaazi Crack Score for IPCALAB is 89 out of 100 as of 25 Jul 2026, a high conviction reading. It is a computed conviction number from the signed stance, how consistent the recent verdicts have been, the quality of the printed structure, and how fresh the review is. It is a transparency signal, not investment advice.

Strike-level option inventory for IPCALAB is unavailable, so BazaarBaazi withholds participant, direction and positioning claims. The editorial chart stance is not substituted for an option-chain observation.

IPCALAB sits in Healthcare (mid cap), indicative market cap ~46,797 cr (indicative), ISIN INE571A01038. The peers BazaarBaazi reads alongside it are GLAND PHARMA LIMITED, Eris Lifesciences Limited, ACUTAAS CHEMICALS LIMITED. A systematic, data-only read on IPCA LABORATORIES LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.

This page is one evergreen URL refreshed in place. The Crack Score and levels re-compute on every BazaarBaazi end-of-day run, and the dated stamp shows the last refresh. The latest signed verdict on IPCALAB is bullish, published in Systematic Read on 21 Jul 2026.

On the 2026-07-24 run of the 500-name BazaarBaazi setup scanner, IPCA LABORATORIES LIMITED sits in the Near-perfect tier with a setup score of 98/100 (technical 100, fundamental 87). The scanner is a deterministic engine over real OHLCV and official filings, refreshed nightly, and it is a signal rather than investment advice.

BazaarBaazi indexes 32 IPCALAB earnings calls going back to 2018-11-30, latest 2026-06-30. Every entry on this page links straight to the transcript PDF the company filed with the exchange, so you read management in the primary source.

IPCA LABORATORIES LIMITED reported a net profit of Rs 307 cr for Q4 FY26 (the quarter ended 31 March 2026). That is +379.3% year on year, a move distorted by a prior-year base effect. The figure is from the company's official NSE filing.

IPCA LABORATORIES LIMITED reported revenue of Rs 2,388 cr for Q4 FY26. That is +6.3% year on year. The figure is from the company's official NSE filing.

BazaarBaazi gives IPCA LABORATORIES LIMITED's Q4 FY26 result a Result Pulse of 69 out of 100, with a verdict of Steady. The Result Pulse is a BazaarBaazi editorial score for the quality of the filed result, not investment advice.

Ipca Laboratories Ltd's two most material recent disclosures are a press release dated 17 Jul 2026, ".Intimation to non-email cases regarding weblink of…", and a disclosure dated 15 Jul 2026, "Copy of Newspaper Publication". Both link to the company's own official filing on the BazaarBaazi stock page.

Yes. Ipca Laboratories Ltd filed a dividend disclosure on 14 Jul 2026, filed as "Record date for the purpose of Dividend is 07-Aug-2026". Any amount shown is the exchange's own record, linked from the BazaarBaazi stock page. A dividend is a declared payout, not a forecast of future returns.

Ipca Laboratories Ltd's most recent board-meeting disclosure on record dated 14 Jul 2026 reads "Notice of Annual General Meeting to be held on August 13, 2026". That is the agenda as filed with the exchange, linked from the BazaarBaazi stock page, and BazaarBaazi adds no claim of its own to it.

Ipca Laboratories Ltd filed a credit-rating disclosure on 07 Jul 2026, recorded with the exchange as "Credit Rating". The detail sits in the linked filing on the BazaarBaazi stock page. A rating action is an agency view on debt, separate from the share price.